🔗 Share this article

A shadow economy for unapproved slimming medications is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Investigational Drug Gaining Traction Via Social Media

The experimental drug, which remains in research studies, is being advertised by online personalities for its supposed weight-reducing effects. Viewers are encouraged to contact these profiles directly for supplier links, while also obtaining promotional offers.

Active Trade on Social Networks

Additionally, a flourishing market exists on Telegram, where groups with thousands of members share “before and after” images, injection guides and assertions of rapid British shipping. Vendors market the substance there before directing buyers to other platforms for transactions.

Understanding Retatrutide

This medication is an experimental injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the next Ozempic.

Healthcare Professionals Voice Worries

However, doctors and pharmacists have warned that the sale of what remains an unlicensed medication in the UK is worrisome and could result in users injecting products of unknown origin.

Several professionals said the popularity for the experimental drug could be linked to the rising cost of licensed slimming products such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed medication that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Some content creators try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still violate medicines, advertising, and customer regulations, potentially leading to fines, prosecution or prison.

Platform Response and Material Removal

According to the social media company, the service has removed problematic content and banned related keywords and query recommendations. The company said it was committed to maintaining the service safe and allocating resources in enhancing enforcement strategies.

Online Marketplace Operations

Research also found groups with up to 9,000 members selling the experimental drug using Telegram's built-in discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up groups with thousands of members, filled with images of slimming results, glowing reviews and step-by-step guides for preparing or injecting at home.

Within minutes of entering one group, a seller posted contact information, where most transactions occur. The seller provided an guidebook and guaranteed delivery within 48 hours. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one asked about body mass, health issues or past usage.

Product Information and Pricing

Inside these communities, posts show dark colored packages with Royal Mail stickers, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at residence with sterile water, or pre-filled injectors usually sold at £160 for 20mg. When questioned how long a pen should be used, vendors give conflicting answers varying between a few weeks to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for Telegram stated it actively monitored dangerous material on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are injecting substances they cannot confirm. Even if the research behind retatrutide is sound, these online products may not contain what they advertise,” said a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the increase in demand to recent cost increases for approved weight-loss medications such as Mounjaro. “With prices rising, patients are using social media. But fake injections are extremely risky. You cannot know what’s contained or whether the environment they were made in was sterile,” she explained.

Her staff has previously encountered individuals injured by self-injection from unconfirmed suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your well-being,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they explained, noting that any item “falsely representing itself as a company investigational product not yet approved … may subject patients to possibly significant health risks”.